Instruction for use: Humegon

ATX Code G03GA02 Menotropins

Active substance: Menotropins

Pharmacological group

Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists

Nosological classification (ICD-10)

N46 Male infertility

Azoospermia, Asthenospermia, Infertility, Infertility male, Marriage is infertile, Dispersion, Violations of spermatogenesis, Oligoastenozoospermia III-IV stage, Oligoastenospermia, Oligozoospermia, Oligospermia, Disorders of testicular functions, Spermatogenesis disorders, Inhibition of spermatogenesis, Yang syndrome

N97 Female infertility

Female infertility in anovulation, Hyperprolactinemic infertility, Hyperprolactinaemia with infertility, Endocrine infertility, Infertility due to hypothalamic-pituitary dysfunction, Infertility infertility, Infertility, Infertility on the background of hyperprolactinaemia, Functional infertility, Marriage is infertile, Infertility of ovarian genesis, Stimulation of the growth of a single follicle

Composition

1 ampoule with lyophilized powder for injection contains 75 IU of follicle stimulating and 75 IU of luteinizing hormone; In a planar cell pack, complete with a solvent in ampoules of 1 ml, in a box of 10 sets.

pharmachologic effect

Pharmacological action - luteinizing, follicle-stimulating.

In women induces maturation of follicles and ovules (before the preovulant stage) in the ovary; In men stimulates spermatogenesis. Increases the production of steroid hormones by the sex glands.

Indication

Infertility due to anovulation or inferior maturation of the follicle (malnutrition of the yellow body) in women, controlled superovulation in infertility treatment programs (in vitro fertilization, etc.) in combination with human chorionic gonadotropin, in men - suppression of spermatogenesis.

Contraindications

Tumors of different localization (including ovaries, testicles, pituitary gland).

Side effects

In women, ovarian hyperstimulation syndrome (discomfort in the lower abdomen); Rarely - the development of large ovarian cysts, ascites, hydrothorax, thromboembolism, skin rash. Increased risk of miscarriage and / or multiple pregnancies (after therapy).

Dosing and Administration

In / m. Women with anovulatory infertility dose selected individually and adjusted it taking into account the concentration of estrogens in the plasma, ultrasound and clinical symptoms; The initial dose (75-150 IU) rises until the appearance of the effect; These effective doses are carried out with maintenance therapy until the preovulatory level of estrogen is reached or the follicle size is increased to 18 mm in diameter.

Men with insufficiency of spermatogenesis - 75 IU (in combination with 1000-2000 IU of rot) daily or 2-3 times a week for 3 months (not less).

Precautionary measures

Before the beginning of treatment it is necessary to exclude anomalies of development of genital organs, primary failure of the ovaries and extragenital endocrinopathies.

storage Conditions

Keep out of the reach of children.